IgG4-Related Disease Clinical Trial
Official title:
National Registry of IgG4-RD in China
The aim of this study is to establish a nation-wide cohort study of IgG4-related disease
(IgG4-RD) in China.
Methods: All the patients fulfilling diagnostic criteria of IgG4-RD (2011) would be enrolled
from multi-centers around China. A online database system has been established.
Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese
IgG4-RD patients; the secondary endpoints including the demographic features,laboratory
characteristics, immunological tests, imaging and pathological features, in addition, the
treatment and prognosis of the disease.
This is a multicenter registry study of IgG4-RD patients. Newly diagnosed IgG4-RD patients
will be recruited from allover the China. Inclusion criteria: patients with definite,
probable, or possible IgG4-RD according to the 2011 comprehensive diagnostic criteria for
IgG4-RD will be recruited. Exclusion criteria: patients with malignancy or other autoimmune
diseases are excluded.
The data will be uploaded through the platform of Chinese Rheumatology Information Platform.
Demographic data, initial symptoms, disease duration, history of allergy, and physical
examination, organ involvements, laboratory findings, radiological and pathological results,
as well as treatment, side effects will be recorded.
This study was approved by the Medical Ethics Committee of PUMCH (Beijing, China). All
patients will signe informed consent.
Statistical Analysis: All parameters are described in the standard summary statistics,
including mean, standard deviation, minimum, and maximum. All statistical analyses will be
performed by SPSS.
Endpoints: The primary endpoint is to investigate the organ involvements of Chinese IgG4-RD
patients. The secondary endpoints including the demographic features,laboratory
characteristics, immunological tests, imaging and pathological features, in addition, the
treatment and prognosis of the disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03368274 -
To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom
|
Phase 4 | |
| Not yet recruiting |
NCT03267875 -
A Laboratory Scan of Patients With Aortic Aneurysms to IgG4 Levels in the Blood
|
N/A | |
| Completed |
NCT02616705 -
Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis
|
||
| Completed |
NCT03669861 -
Safety and Efficacy of Abatacept in IgG4-Related Disease
|
Phase 2 | |
| Recruiting |
NCT05625581 -
Tofatib Treatment for IgG4-related Disease
|
||
| Recruiting |
NCT04125511 -
Characterizing IgG4-RD With 68Ga-FAPI PET/CT
|
Early Phase 1 | |
| Not yet recruiting |
NCT06285539 -
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
|
Phase 2 | |
| Not yet recruiting |
NCT05746689 -
Study of Sirolimus in IgG4-related Disease
|
N/A | |
| Completed |
NCT03690908 -
Infraorbital Nerve Involvement on Magnetic Resonance Imaging in IgG4-related Ophthalmic Disease
|
||
| Completed |
NCT02899039 -
Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease
|
N/A | |
| Recruiting |
NCT04660565 -
Belimumab Treatment for IgG4-related Disease
|
Phase 4 | |
| Recruiting |
NCT01670695 -
A Prospective Cohort Study of IgG4RD in China
|
N/A | |
| Unknown status |
NCT01758393 -
Glucocorticoids in Patients With IgG4-RD
|
Phase 2/Phase 3 | |
| Completed |
NCT02705638 -
Treatment of IgG4-Related Disease With Revlimid and Rituximab
|
Phase 1 | |
| Recruiting |
NCT03473912 -
Meir Medical Center Rheumatologic Biobank
|
||
| Not yet recruiting |
NCT03466970 -
Plasmablast Detection From IgG4-Related Disease Patients
|
N/A |